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Background: Recurrent herpes labialis (RHL) is one of the most common viral infections worldwide. The available
treatments have limited efficacy in preventing the recurrence of ulcerative lesions and reducing the duration of
illness. The objective of this review was to identify the effectiveness of topical corticosteroids in addition to antiviral
therapy in the treatment of RHL infection.
Methods: A systematic review of randomized clinical trials comparing the efficacy of combined therapy (topical
corticosteroids with antiviral) with placebo or antiviral alone in the management of RHL was conducted. MEDLINE,
EMBASE, CINAHL, Web of Science, the Cochrane library, and Google Scholar databases were searched. We used
RevMan software to conduct the meta-analysis. A fixed-effects model was used for mild to moderate heterogeneity,
whereas a random-effects model was used for significant heterogeneity. Heterogeneity among trials was established
using I2 and chi-square test for heterogeneity.
Results: Four studies that fulfilled the selection criteria were included in this review. The total number of
participants across included studies was 1,891 (range, 29 to 1,443). The antiviral drugs used were acyclovir,
famciclovir, and valacyclovir. Corticosteroids used were 1% hydrocortisone and 0.05% fluocinonide. Pooled results
showed that patients receiving combined therapy had a significantly lower recurrence rate of ulcerative lesions
compared to those in both the placebo group (OR, 0.50; 95% CI, 0.39-0.66; P < .001) and the antiviral treatment
alone group (OR, 0.73, 95% CI, 0.58–0.92; P = .007). The healing time was also significantly shorter in combined
therapy in comparison to placebo (P < .001). However, there were no significant differences in healing time
between combined therapy and antiviral alone. The adverse reactions in combined therapy were not significantly
different than the placebo group (OR, 1.09; 95% C, 0.75-1.59; P = .85).
Conclusion: Treatment with combined therapy is safe and more effective than placebo or antiviral alone for
preventing the recurrence of ulcerative lesions in RHL infection.
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Herpes labialis infection is a global public health prob-
lem, with 15 to 40% of the population who experience
symptomatic outbreak [1]. Infection rates are high
among HIV positive patients; about 95% of patients are
seropositive to herpes simplex type I antigen [2]. In de-
veloped countries, one third of the population suffer
from recurrent herpes labialis. (RHL) Between 20 to 40%
of adults become infected with herpes simplex infection
at some point during their lifetime [3]. Detectable serum
antibodies against herpes simplex virus are more preva-
lent in lower socioeconomic groups [4]. Over the last
20 years, prevalence has increased globally and the pre-
vention of RHL poses a big challenge for the 21st cen-
tury. The infection is difficult to eradicate and treatment
has minimal impact on reduction and prevention of
herpes infection. To date, no vaccination has been suc-
cessful so far in humans to prevent the primary infection
of RHL [5].
Herpes simplex labialis (HSL) is a contagious infection
that appears as a rash of the skin, usually involving the
lips but can affect oral membranes, and is characterized
by blisters with pain and occasional itching [6]. There
are different sequential stages of lesion including pro-
drome, redness, papule, vesicular, ulcer, hard crust, dry
flaking, and normal skin (complete epithelisation). Ul-
cerative lesions take longer time to heal, which can
adversely impact quality of life [7]. The diagnosis is typ-
ically based on clinical history and examination; in some
cases, however, specific laboratory tests may be required
[8]. The condition is usually mild, but some patients
may have severe disease that may affect internal organs
or lead to secondary bacterial infections [9].
Current treatment options for HSL include oral anti-
viral drugs, antiviral ointment or other topical applica-
tions (e.g., zinc oxide, zinc sulphate), and anesthetic
creams for symptomatic improvement [10]. Treatment
needs to be initiated promptly to achieve favorable re-
sults. Despite the above mentioned available treatment
options, antivirals are commonly used and can slightly
reduce the duration of herpes lesions by restraining the
multiplication of the virus [11]. However, treatment with
antiviral alone is not very effective and in most cases
only has a minor effect on the duration of illness. There-
fore, researchers have suggested adding corticosteroids
to antiviral agents to increase the responsiveness of le-
sions [12,13] because herpes infection also triggers im-
mune response. However, some controversy exists about
the addition of corticosteroids, as steroidal contents may
worsen the infection by reducing the natural defense
system against the infection [14].
Several countries such as US, Germany, and Netherlands
have approved antiviral with topical corticosteroids for the
treatment of HSL [15]. However, it has not been licensedyet in other countries such as the UK. Therefore, it is im-
portant to understand the role of topical corticosteroid
therapy plus anti-viral agent in the management of RHL
infection. The purpose of this review was to determine the
effectiveness of topical corticosteroids in addition to anti-
viral therapy (combined therapy) compared to antiviral
therapy alone or placebo in the management of RHL infec-
tion using a systematic review and meta-analysis.
Methods
Search methods for identification of studies
We searched electronic databases including MEDLINE
via ovid, EMBASE, CINAHL, Web of Science, and
Cochrane Library. Searches were limited to English-
language reports of human studies from 2000, which
marked the first clinical trial conducted on topical corti-
costeroids and antiviral therapy on humans, to 2013.
A combination of medical subject headings (MeSH)
and key word searches were used to retrieve the relevant
literature in this review. All keywords were entered ei-
ther with “OR” and “AND” boolean operators and were
used with $/* where appropriate.
The following MeSH search terms were used:
“herpes simplex”; “herpes simplex virus”; “herpes labia-
lis”; herpes labialis viruses”; “recurrences”; “recurrent
herpes”; “topical administration”; “anti-infective agents”;
“topical drug administration”; “corticosteroids”; “steroid”;
“antiviral agents”; antiviral drugs”.
The following key words were used:
herpes simplex; herpes labialis; herpes virus; recurrent
herpes labialis; prevention of herpes; treatment of herpes
labialis; antiviral for herpes; antiviral + corticosteroid +
herpes; topical antiviral for herpes; topical treatment + her-
pes; herpes labialis treatment + antiviral + corticosteroid.
Additional studies were sought through a review of
the reference lists of obtained reports and other relevant
reviews on the topic. Grey literature was also searched
using Google Scholar and the ClinicalTrials.gov website
(http://clinicaltrials.gov).
Inclusion and exclusion criteria
Original research articles of randomized controlled clin-
ical trials (RCTs) or controlled clinical trials comparing
the effectiveness of topical corticosteriods in addition to
antiviral (combined therapy) versus antiviral alone or
placebo for the treatment of RHL were eligible for inclu-
sion. Pilot clinical trial studies with similar interventions
and outcomes were also included. We excluded observa-
tional studies and studies that evaluated the treatment
for primary herpes labialis, as well as case reports, con-
ference presentations, and editorials. Studies of healthy
immuno-competent adolescents (12–17 years) and
adults (≥18 years) with a history of RHL were included,
irrespective of gender, socioeconomic status, and race.
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clusion: (1) combined therapy versus antiviral therapy
alone; or (2) combined therapy versus placebo. The pri-
mary outcomes of interest were the development of clas-
sical lesions and reduction in pain. Secondary outcomes
were healing time, adverse events, and reduction in size
of the lesions.
All authors were involved in determining inclusion.
Data collection and analysis
Data collection and analysis was performed using Review
Manager (RevMan Version 5.2, Copenhagen: The Nordic
Cochrane Centre, the Cochrane Collaboration, 2012).
Data from the studies were extracted using data extrac-
tion form. Risk of bias was assessed using the following
key domains: randomization, allocation concealment,
sample size, blinding (single, double or triple), and attri-
tion rate [16].
Odd ratios (ORs) were used for dichotomous out-

















Figure 1 PRISMA flow diagram.with 95% confidence intervals (CI). P < .05 was con-
sidered significant. For continuous outcomes, mean
differences between the groups along with 95% CIs
were measured.
The meta-analysis of continuous data requires means
with variance (or SD) to pool data. Outcomes of con-
tinuous variables were transformed from medians with
interquartile ranges (IQR) to means with SD, using the
following formulas [17]:
1. Conversion of median into mean: χ ≈ a + 2m + b/4
2. Conversion of range into variance: S = b-a/4 = R/4
[X =mean, a = smallest value, b = largest value, m =me-
dian, S = variance, R = range].
A fixed-effects model was used for mild to moderate
heterogeneity, whereas random-effects model was used
for those outcomes when the chi-square test for het-
erogeneity was significant (P < .10) and I2 was higher
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Description of the selected studies
A total of 9,450 studies were originally identified, and 4
were included in the final review (see Figure 1 for
PRISMA flow diagram). All 4 selected studies [18-21]
were RCTs (see Table 1 for study characteristics). Hull
et al. 2010 [18] was a RCT and topical corticosteroids
plus antiviral in the management of RHL was evaluated.
A total of 89 patients were recruited. There were cross-
overs and there were no losses to follow up. Evans et al.
2002 [19] conducted a trial on 380 participants to evalu-
ate the effect of ME-609 (topical corticosteroid with
antiviral) in comparison to placebo. Hull et al. 2009 [20]
was a small trial on 39 participants in which valacyclovir
and clobetasol gel were compared with placebo. Spruance
et al. 2000 [21] conducted a trial on 29 participants where
topical corticosteroid with valacyclovir 2gm was compared
with antiviral alone. The antiviral used was acyclovir in 2
studies [18,19], famciclovir and valacyclovir in each of the
other 2 studies [20,21]. The average number of episodes of
the RHL in the participants ranged from 4.5 to 5.6
episodes per year.
The risk of bias was assessed in the selected studies.
The total number of participants included in theTable 1 Characteristics of randomized controlled trials includ
Study Setting Participants (n) Groups (n
Hull et al. 2010 [18] 51 sites in the United
States and 4 sites in
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(n = 12)studies was 1,892 (range, 29 to 1,443). All four selected
studies appropriately reported the process of random-
isation. Most of the randomisation achieved 1:1 treat-
ment to control ratios whilst Hull et al. (2010) [18]
performed 2.7:1 for the treatment and placebo group
respectively [18]. Allocation concealment was also re-
ported in all four selected studies. Therefore, a mini-
mum risk of selection bias was expected in the selected
studies as a result of allocation concealment. The par-
ticipants as well as personnel involved in providing care
(medication) were blinded in all four selected studies.
All studies reported the use of identical looking sub-
stances in both group in similar packing and labels.
Two studies clearly reported the blinding of personnel
assessing the outcome [18-20]. On the other hand, it
was unclear in two studies [19,21]. The intention to
treat analysis was used in all four studies and risk of
bias was minimal in relation to drop outs and loss to
follow up patients’ data.
Effects of interventions
The development of the ulcerative lesions
Three studies reported on this outcome [18-20]. There
was no significant heterogeneity (I2 = 20%) found amongsted in the review
) Male, n (%) Frequency of RHL
(mean episodes/year)
n 406 (28) 5.6
ream (5% Acyclovir, 1%
rtisone) (n = 601)
(5% in ME-609 vehicle)
(vehicle) (n = 232)
n 76 (20) 5.3
ream (5% Acyclovir,
ocortisone) (n = 190)
(n = 190)
n 13 (33) 4.5
cyclovir (2 g 2×/day for 1 day)
cal Clobetasol gel (0.05% 2×/day
s) (n = 20)
(n = 19)
n 14 (29) 5
ciclovir (Famvir, 500 mg 3×/day
s) plus topical Fluocinonide (0.05%
l 3×/day for 5 days) (n = 17)
vir and topical vehicle control
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not significant (P = .29). Meta-analysis showed a statisti-
cally significant reduction in the development of ulcerative
lesions, demonstrating that the odds of the occurrence of
ulcerative lesions were 50% less likely in the intervention
group as compared to placebo (OR, 0.50; 95% CI, 0.39-
0.66; P < .001).
Similarly, the comparison of combined therapy with
antiviral alone also showed a significant reduction in the
development of ulcerative lesions in the intervention
arm as compared to the control (Figure 3) (OR, 0.73;
95% CI, 0.58-0.92; P = .007). There was moderate hetero-
geneity among trials (I2 = 56%). Chi-square test for het-
erogeneity was insignificant (P = .13).
Healing time for ulcerative lesions (complete epithelisation)
The meta-analysis of 407 patients showed a significant
reduction of 1.49 days in the healing time for ulcerative
lesions in the combine therapy group in compared to
the placebo group (Figure 4) (95% CI, −1.99 to −0.98;
P < .001). This outcome was observed on the based of
the healing time from the first sign of lesion until
complete epithelisation. All studies showed significant
reduction in healing time in the intervention group
compared to placebo and there was a moderate hetero-
geneity between the studies (I2 = 53%).
No significant difference was found in the healing time
for ulcerative lesions between the combined therapy and
the treatment with antiviral alone (mean difference = −1.68;
95% CI, −4.52 to 1.16) in the pooled data of 357 patients
(Figure 5). There was a highly significant heterogeneity be-
tween the selected studies (I2 = 93%), so the random effect
model was used.
The effect of treatment on pain or tenderness in the lesion
In the comparison of topical corticosteroid plus antiviral
with placebo, two of the three studies did not show any
significant reduction in pain or tenderness in the inter-
vention group as compared to the placebo. However, the
overall effect revealed a significant reduction (OR, 0.59;
95% CI, 0.45-0.77; P < .001). An effect of a smallerFigure 2 Forest plot of comparison: topical corticosteroid plus antiviral
of ulcerative lesions.magnitude was observed for reduction in pain and ten-
derness when the combine therapy was compared with
antiviral alone. There was a significant heterogeneity
(I2 = 67%) between the 2 studies in this analysis. The
overall effect using the pooled data of 618 participants
showed no significant difference in pain between topical
corticosteroid plus antiviral group compared to antiviral
alone (OR, 0.32; 95%CI, 0.03- 3.76; P = .37).
Adverse reactions
The most common adverse reactions appeared were dry-
ness, irritation, and stinging symptoms, which were re-
lated to topical application and not specifically due to
the corticosteroid component. Studies showed no signifi-
cant difference in proportion of adverse reaction ob-
served between the intervention and the placebo group.
There was no heterogeneity between the selected studies
(I2 = 0%). The overall effect also showed no significant
difference between the intervention and the placebo
group (OR, 1.09; 95% CI, 0.75-1.59; P = .65).
The odds of the occurrence of adverse reactions were
37% more likely in the antiviral alone as compared to
the combine therapy group; however, the effect was not
statistically significant (OR, 1.37; 95% CI, 0.97-1.95,
P = .08). Heterogeneity between the two groups was not
statistically significant (I2 = 28%).
Discussion
To date, this is the first meta-analysis to determine the
effect of adding topical corticosteroids in the treatment
of RHL. The results of this review show that addition of
topical corticosteroids to antiviral therapy has significant
benefit compared to either antiviral therapy alone or pla-
cebo. The review was conducted on RCTs only, which
helped in producing rigorous findings about the effect-
iveness of adding topical corticosteroids in the treatment
of RHL.
This review indicates that the chance of developing ul-
cerative lesions is reduced in patients who receive topical
corticosteroids in addition to antiviral treatment in com-
parison to placebo or antiviral treatment alone. Evidencegroup versus placebo, outcome: Pooled odds ratio of development
Figure 3 Forest plot of comparison: topical corticosteroid plus antiviral group versus antiviral alone, outcome: Pooled odds ratio for
development of ulcerative lesions.
Arain et al. BMC Infectious Diseases  (2015) 15:82 Page 6 of 8shows that the treatment with antiviral alone decreases
the duration of ulcerative lesions in herpes labialis [22,23].
However, in most cases antiviral treatment alone does not
prevent the development of ulcerative lesion [12].
Pain is another important determinant of the morbid-
ity in RHL [6]. A 24% reduction in the development of
pain in the lesion was an important outcome observed.
One study reported a 26% faster improvement in pain
among those patients who received topical penciclovir
than those who received a placebo [23]. However, a re-
view of 10 antiviral studies showed that none of them
had any significant effect on pain reduction [10]. Fur-
thermore, topical anesthetic treatment alone also did not
show any significant impact on pain reduction [24].
Photodynamic therapy is effective in relieving pain in
the lesions [25].
The adverse reactions were lower in corticosteroids
group than those appeared in the antiviral group alone.
A non-randomized clinical trial to determine the safety
and tolerance of topical corticosteroids plus antiviral in
adolescents found that the treatment was well tolerated
and safe [13]. Studies on animals have also shown that
the treatment with acyclovir with hydrocortisone is su-
perior to antiviral alone without any significant adverse
reactions [26].
The healing time was significantly reduced (around
1.5 days) in the treatment group in comparison to pla-
cebo. A review on topical acyclovir revealed that 9 of 13
studies did not show any significant effect on healing
time, while 4 studies demonstrated significant reductionsFigure 4 The comparison of effect of corticosteroid plus antiviral and
sign until complete epithelisation.ranging from 0.5 to 2 days [27]. Treatment with topical
penciclovir alone reduced healing time by 0.5 days in
two clinical trials of 3,057 and 1,573 patients [28,29].
Oral antiviral treatment with famciclovir has shown a re-
duction of approximately 2 days in healing time [30].
Another trial with valacyclovir 2 grams on 1,524 patients
found a median reduction in healing time by 1.5 days
[31], which is comparable to the reduction in the healing
time with topical corticosteroids plus antiviral demon-
strated in this review.
There are a number of limitations of this study. First,
the meta-analysis in this study was conducted on a small
number of studies, which is likely attributable to the lim-
ited availability of topical corticosteroid plus antiviral
treatment. The statistical tests to identify publication
bias could not be performed due to the small number of
studies in the review. Second, the selected studies used
different form and type of antivirals (oral and topical).
The topical antiviral agents that are most commonly rec-
ommended to treat RHL include acyclovir 5% cream,
penciclovir 1% cream and docosanol 10% cream. Most
of these preparations need to be applied every 2 hours
from the time of prodrome until complete healing [32].
Unlike topical agents, systemic medications enable
greater drug exposure, rapid access to site of viral repli-
cation, better biocompatibility, less frequent dosing, and
improved compliance. Systemic antiviral agents may be
administered orally or intravenously. Acyclovir has a
short half-life and multiple doses are required to main-
tain an optimum drug levels in serum. Famciclovir andplacebo on the healing time for ulcerative lesions from the first
Figure 5 The comparison of effect of corticosteroid plus antiviral and antiviral alone on the healing time for ulcerative lesions from
the first sign until complete epithelisation.
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convenient for patients [33]. The reduction in healing
time for oral antiviral treatment is generally higher than
topical antivirals; this may have had an impact on the out-
comes of this study. Finally, 2 studies used ultraviolet-
induced cold sores, which may lead to more severe
outbreaks. Ultraviolet light is known to be a stimulus for
the reactivation of herpes simplex virus. Ultraviolet-
induced cold sores may develop very rapidly [34,35]. How-
ever, in this study, we found that the combination therapy
was equally effective for the ultraviolet-induced cold sores.Conclusion
The addition of the steroidal component along with an-
tivirals improves treatment of RHL. Adverse reactions
are lower in topical corticosteroid plus antivirals treat-
ment than treatment with antiviral alone. Thus, the
treatment with topical corticosteroid plus antiviral alone
is safe and more effective in preventing the development
of ulcerative lesions than antiviral alone or placebo. The
healing time may not be further reduced with topical
corticosteroid plus antiviral than with antiviral treatment
alone.
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